FDA gives approval for Pluristem to resume stem cell treatment trial

09/16/2013 | Bloomberg Businessweek

The FDA removed a clinical hold on Pluristem Therapeutics' placenta-based stem cell treatment PLX, clearing the way for the therapy's midstage trial. PLX is being tested against intermittent claudication, a symptom of peripheral artery disease. The hold came after a single patient's allergic reaction, according to the company.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA